SEC Filing Summary
Registrant and period: The supplied filing is AmpliPhi Biosciences Corporation’s unaudited Form 10-Q for the quarter ended March 31, 2018, filed May 15, 2018. It does not identify Armata Pharmaceuticals, Inc. as the registrant; investors should verify the company and filing identity.
Business Context
AmpliPhi was developing bacteriophage therapies for antibiotic-resistant infections, including candidates targeting Staphylococcus aureus (AB-SA01) and Pseudomonas aeruginosa (AB-PA01). It also described single-patient expanded-access treatments and plans to pursue chronic rhinosinusitis and cystic fibrosis programs with partners or outside funding. The company had no product sales and expected no product revenue in the foreseeable future.
Financial Performance and Position
| Metric | Q1 2018 | Q1 2017 / prior balance date |
|---|---|---|
| Revenue | $0 | $29,000 |
| Research and development expense | $1.464 million | $1.490 million |
| General and administrative expense | $1.591 million | $1.898 million |
| Total operating expenses | $3.055 million | $3.388 million |
| Net loss | $3.134 million | $3.246 million |
| Net loss per share | $0.24 | $1.94 |
| Operating cash used | $3.536 million | $3.299 million |
| Cash and cash equivalents | $8.206 million | $5.132 million at Dec. 31, 2017 |
| Total current assets / current liabilities | $8.743 million / $1.775 million | $5.385 million / $1.968 million at Dec. 31, 2017 |
| Total liabilities | $3.109 million | $3.407 million at Dec. 31, 2017 |
There was no product revenue to report meaningful operating margins. The filing reports no conventional borrowing balance in the presented balance sheet; liabilities included $187,000 of derivative liabilities and a $1.147 million deferred tax liability. The company reported a $397.3 million accumulated deficit. Cash provided by financing was $6.610 million, principally from equity offerings and warrant exercises; investing cash flow was zero. No off-balance-sheet arrangements were reported.
Material Changes Versus the Prior Comparable Period
- Revenue fell from $29,000 to zero. Operating expenses declined by $333,000, mainly as general and administrative costs fell by $307,000; research and development spending was broadly flat.
- Net loss narrowed by $112,000, while operating cash use increased by $237,000.
- Cash rose from year-end 2017, largely reflecting two Q1 equity offerings and warrant exercises. The January and March offerings generated approximately $6.2 million net in total; Q1 net financing cash flow was $6.610 million.
- Shares issued and outstanding increased from 9,498,928 at December 31, 2017 to 16,464,464 at March 31, 2018. The March offering included shares purchased by an entity affiliated with two directors.
Outlook, Risks, and Unusual Items
- Liquidity and going concern: Recurring losses and negative operating cash flows raised substantial doubt about the company’s ability to continue as a going concern. Management estimated existing cash would fund planned operations into the fourth quarter of 2018, but said additional capital was necessary for continued operations.
- Outlook: Management expected significant and increasing operating losses for several years and no product revenue until a candidate is developed and approved. No quantified revenue or earnings guidance was provided.
- Funding risk: If financing is unavailable on acceptable terms, the company said it might defer or reduce spending, curtail programs, relinquish product rights, sell assets, pursue a sale, or cease operations. Additional equity financing could dilute shareholders.
- Development and regulatory risks: Phage therapy was a novel approach with no approved products identified in the filing. Clinical efficacy, manufacturing scale-up, regulatory requirements, trial timing, and whether expanded-access data would support development remained uncertain.
- Expanded access: The company warned that treatments could carry unreimbursed manufacturing costs, divert resources, and fail to provide clinical evidence acceptable to regulators.
- Warrants and accounting: Derivative liabilities were measured using Level 3 inputs. A $79,000 Q1 loss from the fair-value change partly offset lower expenses; 217,400 warrants were exercised for $198,000.
- Contingencies and controls: The company reported no legal proceeding expected by management to have a material adverse effect. Management said disclosure controls were effective at a reasonable-assurance level and reported no material quarterly change in internal control over financial reporting.
Important Facts for Investors to Verify
- Confirm that this AmpliPhi 2018 Q1 filing is the intended filing for the requested company, Armata Pharmaceuticals, Inc.
- Verify current cash runway, burn rate, and subsequent financing needs against later filings; the stated runway extended only into Q4 2018.
- Review subsequent clinical, regulatory, and manufacturing developments for AB-SA01, AB-PA01, and expanded-access programs.
- Assess dilution from the Q1 share issuance and the outstanding 8,304,032 warrants and 1,116,043 options at March 31, 2018.
- Check later disclosures regarding the going-concern uncertainty, financing availability, and any changes to development plans.